Skip to main content

Advertisement

SpringerLink
Log in

p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant neoplasms worldwide. The p53 gene is frequently mutated in some histological subtypes of HCC. The role of p53 mutations and polymorphic variant of codon 72 in the prognosis of disease is still unclear. The p53 tumor suppressor gene Arg72Pro polymorphism has been associated with HCC. However, results were inconsistent. This meta-analysis was performed to estimate the association between p53 Arg72Pro polymorphism and HCC or HCC infected by HBV/HCV.

Methods

Electronic search of PubMed was conducted to select studies. Studies containing available genotype frequencies of Arg72Pro were chosen, and pooled odds ratio (OR) with 95 % confidence interval (CI) was used to assess the association.

Results

Ten published studies, including 1,371 HCC cases and 2,517 controls were identified. The overall results suggested that the variant genotypes were associated with the HCC risk (Pro/Pro vs. Pro/Arg + Arg/Arg: OR 1.355, 95 % CI 1.041–1.764, p = 0.024). In the stratified analysis, individuals with the Pro/Pro in the recessive model had increased risk of HCC (OR 1.927, 95 % CI 1.127–3.297, p = 0.017) in Caucasian. A symmetric funnel plot, the Begg’s test, was suggestive of the lack of publication bias. There was no association between the p53 codon 72 polymorphism and HBV/HCV-positive HCC.

Conclusion

This meta-analysis suggests that p53 condon 72 Pro/Progenotypes are associated with increased risk of HCC in Caucasian. To validate this association, further studies with larger participants worldwide are needed to examine the associations between this polymorphism and HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, et al. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988;108(3):390–401

    Article  PubMed  Google Scholar 

  2. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994;17(2):71–91

    Article  CAS  PubMed  Google Scholar 

  3. Tsai JF, Chang WY, Jeng JE, et al. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 1994;44(1):92–95

    Article  CAS  PubMed  Google Scholar 

  4. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61(10):1942–1956

    Article  CAS  PubMed  Google Scholar 

  5. Akashi M, Koeffler HP. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998;41(1):172–199

    Article  CAS  PubMed  Google Scholar 

  6. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990;348(6303):747–749. doi:https://doi.org/10.1038/348747a0

    Article  CAS  PubMed  Google Scholar 

  7. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995;14(1):3–15

    Article  CAS  PubMed  Google Scholar 

  8. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009;9(10):701–713. pii:nrc2693

    Article  CAS  PubMed  Google Scholar 

  9. Ara S, Lee PS, Hansen MF, et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18(16):4961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007;121(7):1481–486. doi:https://doi.org/10.1002/ijc.22833

    Article  CAS  PubMed  Google Scholar 

  11. Kawajiri K, Nakachi K, Imai K, et al. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14(6):1085–1089

    Article  CAS  PubMed  Google Scholar 

  12. Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995;16(9):2233–2236

    Article  CAS  PubMed  Google Scholar 

  13. De Vecchi G, Verderio P, Pizzamiglio S, et al. The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev 2008;32(2):140–143 doi:https://doi.org/10.1016/j.cdp.2008.06.003

    Article  PubMed  Google Scholar 

  14. Khaliq S, Hameed A, Khaliq T, et al. P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test 2000;4(1):23–29. doi:https://doi.org/10.1089/109065700316435

    Article  CAS  PubMed  Google Scholar 

  15. Sjalander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17(6):1313–1316

    Article  CAS  PubMed  Google Scholar 

  16. Sjalander A, Birgander R, Athlin L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16(7):1461–1464

    Article  CAS  PubMed  Google Scholar 

  17. Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology 1999;29(3):697–702. pii:S027091399900110X

    Article  CAS  PubMed  Google Scholar 

  18. Leveri M, Gritti C, Rossi L, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett 2004;208(1):75–79. doi:https://doi.org/10.1016/j.canlet.2004.02.016

    Article  CAS  PubMed  Google Scholar 

  19. Anzola M, Cuevas N, Lopez-Martinez M, et al. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett 2003;193(2):199–205

    Article  CAS  PubMed  Google Scholar 

  20. Zhu ZZ, Cong WM, Liu SF, et al. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection. Cancer Lett 2005;229(1):77–83. pii: S0304-3835(05)00387-3

    Article  CAS  PubMed  Google Scholar 

  21. Okada F, Shiraki T, Maekawa M, et al. A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Lett 2001;172(2):137–142

    Article  CAS  PubMed  Google Scholar 

  22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22(4):719–748

    CAS  PubMed  Google Scholar 

  23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–188. pii: 0197-2456(86)90046-2

    Article  CAS  PubMed  Google Scholar 

  24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Park JO, Stephen Z, Sun C, et al. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Mol Imaging 2011;10(1):69–77

    Article  CAS  PubMed  Google Scholar 

  26. Shirakawa H, Kuronuma T, Nishimura Y, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009;34(3):649–656

    CAS  PubMed  Google Scholar 

  27. Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs 2011;25(5):275–284. doi:https://doi.org/10.2165/11595360-000000000-00000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393(6682):229–234. doi:https://doi.org/10.1038/30400

    Article  CAS  PubMed  Google Scholar 

  29. Gottschlich S, Maune S, Preugschat J, et al. p53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Res 2000;20(4):2613–2616

    CAS  PubMed  Google Scholar 

  30. Sourvinos G, Rizos E, Spandidos DA. p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 2001;37(7):572–578

    Article  CAS  PubMed  Google Scholar 

  31. Hsieh YY, Lin CS. P53 codon 11, 72, and 248 gene polymorphisms in endometriosis. Int J Biol Sci 2006;2(4):188–193

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chang CC, Hsieh YY, Tsai FJ, et al. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril 2002;77(1):43–45. pii: S0015028201029387

    Article  PubMed  Google Scholar 

  33. Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994;44(5):266–270

    Article  CAS  PubMed  Google Scholar 

  34. Yu MW, Lien JP, Chiu YH, et al. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997;27(2):320–330

    Article  CAS  PubMed  Google Scholar 

  35. Tang ZY. Hepatocellular carcinoma—cause, treatment and metastasis. World J Gastroenterol 2001;7(4):445–454

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000;85(4):498–502

    Article  CAS  PubMed  Google Scholar 

  37. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27(1):273–278. doi:https://doi.org/10.1002/hep.510270140

    Article  CAS  PubMed  Google Scholar 

  38. Honda M, Kaneko S, Shimazaki T, et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000;31(6):1351–1359. doi:https://doi.org/10.1053/jhep.2000.7985

    Article  CAS  PubMed  Google Scholar 

  39. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001;75(3):1401–1407. doi:https://doi.org/10.1128/JVI.75.3.1401-1407.2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33(3):357–365. doi:https://doi.org/10.1038/ng1093

    Article  CAS  PubMed  Google Scholar 

  41. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23(19):3328–3337. doi:https://doi.org/10.1038/sj.onc.1207428

    Article  CAS  PubMed  Google Scholar 

  42. Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006;38(10):1133–1141. pii:ng1879

    Article  CAS  PubMed  Google Scholar 

  43. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108(2):196–199. doi:https://doi.org/10.1002/ijc.11548

    Article  CAS  PubMed  Google Scholar 

  44. Yoon YJ, Chang HY, Ahn SH, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;29(6):1192–1196. doi:https://doi.org/10.1093/carcin/bgn090

    Article  CAS  PubMed  Google Scholar 

  45. Sumbul AT, Akkiz H, Bayram S, et al. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep 2012;39(2):1639–1647. doi:https://doi.org/10.1007/s11033-011-0903-2

    Article  CAS  PubMed  Google Scholar 

  46. Wang SH, Yeh SH, Lin WH, et al. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology.2009;50(5):1392–1402. doi:https://doi.org/10.1002/hep.23163

    Article  CAS  PubMed  Google Scholar 

  47. Peng T, Yan L, Lu Z, et al. Association of p53 codon 72 polymorphism with increased risk of hepatocellular carcinoma in Ganxi population of China. Chin J Surg 2004;42(5):313–314

    Google Scholar 

  48. Mah YH, Hsu CS, Liu CH, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int 2011;5(3):814–821. doi:https://doi.org/10.1007/s12072-010-9248-5

    Article  PubMed  Google Scholar 

  49. Ezzikouri S, El Feydi AE, Chafik A, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 2007;37(9):748–754. pii: HEP126

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was financially supported by foundations (No. 30960152, No. 2008C043M, No. GREKF10-07).

Author information

Authors and Affiliations

  1. Laboratory of Molecular Genetics of Aging and Tumor, Faculty of Life Science and Technology, Faculty of Environmental Science and Engineering, Kunming University of Science and Technology, 727 Jing Ming Nan Road, Chenggong County, Kunming, 650500, Yunnan, China

    Shuting Jia, Wenru Tang & Ying Luo

Authors
  1. Shuting Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenru Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuting Jia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jia, S., Tang, W. & Luo, Y. p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis. Hepatol Int 7, 669–675 (2013). https://doi.org/10.1007/s12072-012-9389-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-012-9389-9

Keywords

Search

Navigation